Cargando…

Ibrutinib-Induced Paronychia and Periungual Pyogenic Granuloma

Nail changes elicited by Ibrutinib are relatively infrequent but are reported in the literature. Herein, we report on two cases that developed Ibrutinib-induced nail toxicities. A 63-year-old female, with relapsing mantle cell lymphoma on Ibrutinib 560mg/day for seven months developed paronychia, on...

Descripción completa

Detalles Bibliográficos
Autores principales: Alamri, Awadh, Alghamdi, Yara, Alghamdi, Atheer, Albogami, Dhai B, Shahada, Omar, AlHarbi, Aseel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874258/
https://www.ncbi.nlm.nih.gov/pubmed/36712781
http://dx.doi.org/10.7759/cureus.32943
_version_ 1784877768899559424
author Alamri, Awadh
Alghamdi, Yara
Alghamdi, Atheer
Albogami, Dhai B
Shahada, Omar
AlHarbi, Aseel
author_facet Alamri, Awadh
Alghamdi, Yara
Alghamdi, Atheer
Albogami, Dhai B
Shahada, Omar
AlHarbi, Aseel
author_sort Alamri, Awadh
collection PubMed
description Nail changes elicited by Ibrutinib are relatively infrequent but are reported in the literature. Herein, we report on two cases that developed Ibrutinib-induced nail toxicities. A 63-year-old female, with relapsing mantle cell lymphoma on Ibrutinib 560mg/day for seven months developed paronychia, onychomadesis, Beau’s lines, nail fragility, and brittleness over fingernails and toenails. On the other hand, an 80-year-old male with chronic lymphoid leukemia developed a bloody papule with hemorrhagic crust and nail-plate abnormalities. Skin toxicities manifested eight months after initiating Ibrutinib therapy. From a clinical perspective, Ibrutinib-induced chronic paronychia and PG have been established. All other PG triggers have been ruled out. After the cessation of Ibrutinib, the PG improved for both cases. The exact pathogenesis of PG induced by Ibrutinib is not yet understood but it had been compared to retinoid-related changes. Thus, further research and reporting of similar cases should be done to further understand the pathophysiology of such manifestations.
format Online
Article
Text
id pubmed-9874258
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-98742582023-01-26 Ibrutinib-Induced Paronychia and Periungual Pyogenic Granuloma Alamri, Awadh Alghamdi, Yara Alghamdi, Atheer Albogami, Dhai B Shahada, Omar AlHarbi, Aseel Cureus Dermatology Nail changes elicited by Ibrutinib are relatively infrequent but are reported in the literature. Herein, we report on two cases that developed Ibrutinib-induced nail toxicities. A 63-year-old female, with relapsing mantle cell lymphoma on Ibrutinib 560mg/day for seven months developed paronychia, onychomadesis, Beau’s lines, nail fragility, and brittleness over fingernails and toenails. On the other hand, an 80-year-old male with chronic lymphoid leukemia developed a bloody papule with hemorrhagic crust and nail-plate abnormalities. Skin toxicities manifested eight months after initiating Ibrutinib therapy. From a clinical perspective, Ibrutinib-induced chronic paronychia and PG have been established. All other PG triggers have been ruled out. After the cessation of Ibrutinib, the PG improved for both cases. The exact pathogenesis of PG induced by Ibrutinib is not yet understood but it had been compared to retinoid-related changes. Thus, further research and reporting of similar cases should be done to further understand the pathophysiology of such manifestations. Cureus 2022-12-25 /pmc/articles/PMC9874258/ /pubmed/36712781 http://dx.doi.org/10.7759/cureus.32943 Text en Copyright © 2022, Alamri et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Alamri, Awadh
Alghamdi, Yara
Alghamdi, Atheer
Albogami, Dhai B
Shahada, Omar
AlHarbi, Aseel
Ibrutinib-Induced Paronychia and Periungual Pyogenic Granuloma
title Ibrutinib-Induced Paronychia and Periungual Pyogenic Granuloma
title_full Ibrutinib-Induced Paronychia and Periungual Pyogenic Granuloma
title_fullStr Ibrutinib-Induced Paronychia and Periungual Pyogenic Granuloma
title_full_unstemmed Ibrutinib-Induced Paronychia and Periungual Pyogenic Granuloma
title_short Ibrutinib-Induced Paronychia and Periungual Pyogenic Granuloma
title_sort ibrutinib-induced paronychia and periungual pyogenic granuloma
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874258/
https://www.ncbi.nlm.nih.gov/pubmed/36712781
http://dx.doi.org/10.7759/cureus.32943
work_keys_str_mv AT alamriawadh ibrutinibinducedparonychiaandperiungualpyogenicgranuloma
AT alghamdiyara ibrutinibinducedparonychiaandperiungualpyogenicgranuloma
AT alghamdiatheer ibrutinibinducedparonychiaandperiungualpyogenicgranuloma
AT albogamidhaib ibrutinibinducedparonychiaandperiungualpyogenicgranuloma
AT shahadaomar ibrutinibinducedparonychiaandperiungualpyogenicgranuloma
AT alharbiaseel ibrutinibinducedparonychiaandperiungualpyogenicgranuloma